IMPACT SCORE JOURNAL RANKING CONFERENCE RANKING Conferences Journals Workshops Seminars SYMPOSIUMS MEETINGS BLOG LaTeX 5G Tutorial Free Tools

Search About Journals, Conferences, and Book Series

Investigational New Drugs

Impact, Factor and Metrics, Impact Score, Ranking, h-index, SJR, Rating, Publisher, ISSN, and More

Last Updated on October 31, 2023

Impact Score

2022-2023

3.62

h-Index

2022-2023

 94

Rank

2022-2023

 4625

SJR

2022-2023

 0.943

Note: The impact score or impact index shown here is equivalent to the average number of times documents published in a journal/conference in the past two years have been cited in the current year (i.e., Cites / Doc. (2 years)). It is based on Scopus data and can be a little higher or different compared to the impact factor (IF) produced by Journal Citation Report. Please refer to the Web of Science data source to check the exact journal impact factor ™ (Thomson Reuters) metric.

Important Metrics and Factor

Title Investigational New Drugs
Abbreviation Investig. New Drugs
Publication Type Journal
Subject Area, Categories, Scope Pharmacology (Q1); Pharmacology (medical) (Q1); Oncology (Q2)
h-index 94
Overall Rank/Ranking 4625
SCImago Journal Rank (SJR) 0.943
Impact Score 3.62
Publisher Kluwer Academic Publishers
Country Netherlands
ISSN 01676997, 15730646
Best Quartile Q1
Coverage History 1983-2022




Aim and Scope


The development of new anticancer agents is one of the most rapidly changing aspects of cancer research. Investigational New Drugs provides a forum for the rapid dissemination of information on new anticancer agents. The papers published are of interest to the medical chemist, toxicologist, pharmacist, pharmacologist, biostatistician and clinical oncologist. Investigational New Drugs provides the fastest possible publication of new discoveries and results for the whole community of scientists developing anticancer agents.

Each issue contains original articles dealing with anticancer drug development. Other sections are devoted to invited review articles and letters to the editor.


About Investigational New Drugs


Investigational New Drugs is a journal covering the technologies/fields/categories related to Pharmacology (Q1); Pharmacology (medical) (Q1); Oncology (Q2). It is published by Kluwer Academic Publishers. The overall rank of Investigational New Drugs is 4625. According to SCImago Journal Rank (SJR), this journal is ranked 0.943. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come. SJR acts as an alternative to the Journal Impact Factor (or an average number of citations received in last 2 years). This journal has an h-index of 94. The best quartile for this journal is Q1.

The ISSN of Investigational New Drugs journal is 01676997, 15730646. An International Standard Serial Number (ISSN) is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic. Investigational New Drugs is cited by a total of 1792 articles during the last 3 years (Preceding 2022).


Investigational New Drugs Impact IF 2022-2023


The Impact IF 2022 of Investigational New Drugs is 3.62, which is computed in 2023 as per its definition. Investigational New Drugs IF is decreased by a factor of 0.27 and approximate percentage change is -6.94% when compared to preceding year 2021, which shows a falling trend. The impact IF, also denoted as Journal impact score (JIS), of an academic journal is a measure of the yearly average number of citations to recent articles published in that journal. It is based on Scopus data.

Table Setting

Investigational New Drugs Impact IF 2023 Prediction


Impact IF 2022 of Investigational New Drugs is 3.62. If the same downward trend persists, Impact IF may fall in 2023 as well.


Impact IF Trend


Year wise Impact IF of Investigational New Drugs. Based on Scopus data.


Year Impact IF
2023/2024 Coming Soon
2022 3.62
2021 3.89
2020 3.29
2019 3.52
2018 2.70
2017 3.69
2016 3.71
2015 3.71
2014 3.27

Investigational New Drugs h-index


  Table Setting

Investigational New Drugs has an h-index of 94. It means 94 articles of this journal have more than 94 number of citations. The h-index is a way of measuring the productivity and citation impact of the publications. The h-index is defined as the maximum value of h such that the given journal/author has published h papers that have each been cited at least h number of times.




Investigational New Drugs ISSN


The ISSN of Investigational New Drugs is 01676997, 15730646. ISSN stands for International Standard Serial Number.

An ISSN is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic.

Table Setting

Investigational New Drugs Rank and SCImago Journal Rank (SJR)


The overall rank of Investigational New Drugs is 4625. According to SCImago Journal Rank (SJR), this journal is ranked 0.943. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come.

SJR of Investigational New Drugs by Year


Year SJR
2023/2024 Coming Soon
2022 0.943
2021 0.965
2020 1.254
2019 1.493
2018 1.135
2017 1.573
2016 1.340
2015 1.388
2014 1.093

Ranking of Investigational New Drugs by Year


Year Ranking
2023/2024 Coming Soon
2022 4625
2021 4318
2020 3070
2019 2243
2018 3613
2017 2126
2016 2852
2015 2716
2014 3802

Investigational New Drugs Publisher


Table Setting

Investigational New Drugs is published by Kluwer Academic Publishers. It's publishing house is located in Netherlands. Coverage history of this journal is as following: 1983-2022. The organization or individual who handles the printing and distribution of printed or digital publications is known as Publisher.


Call For Papers


Visit the official website of the journal/conference to check the further details about the call for papers.


Abbreviation


The IS0 4 standard abbreviation of Investigational New Drugs is Investig. New Drugs. This abbreviation ('Investig. New Drugs') is well recommended and approved for the purpose of indexing, abstraction, referencing and citing goals. It meets all the essential criteria of ISO 4 standard.

ISO 4 (International Organization for Standardization 4) is an international standard that defines a uniform and consistent system for abbreviating serial publication titles and journals.


How to publish in Investigational New Drugs


If your research field is/are related to Pharmacology (Q1); Pharmacology (medical) (Q1); Oncology (Q2), then please visit the official website of this journal.


Acceptance Rate


The acceptance rate/percentage of any academic journal/conference depends upon many parameters. Some of the critical parameters are listed below.

  • The demand or interest of researchers/scientists in publishing in a specific Journal/Conference.
  • Peer review complexity and timeline.
  • The mix of unsolicited and invited submissions.
  • The time it takes from manuscript submission to final publication.
  • And Many More.

It is essential to understand that the acceptance rate/rejection rate of papers varies among journals. Some Journals considers all the manuscripts submissions as a basis of acceptance rate computation. On the other hand, few consider the only manuscripts sent for peer review or few even not bother about the accurate maintenance of total submissions. Hence, it can provide a rough estimation only.

The best way to find out the acceptance rate is to reach out to the associated editor or to check the official website of the Journal/Conference.



Frequently Asked Questions (FAQs)


What's the latest impact IF of the Investigational New Drugs?

Investigational New Drugs latest impact IF is 3.62. It's evaluated in the year 2022. The highest and the lowest impact IF or impact score of this journal are 3.89 (2021) and 2.70 (2018), respectively, in the last 9 years. Moreover, its average IS is 3.49 in the previous 9 years.


What's the SCImago Journal Rank (SJR) of the Investigational New Drugs?

The Investigational New Drugs has an SJR (SCImago Journal Rank) of 0.943, according to the latest data. It is computed in the year 2023. In the past 9 years, this journal has recorded a range of SJR, with the highest being 1.573 in 2017 and the lowest being 0.943 in 2022. Furthermore, the average SJR of the Investigational New Drugs over the previous 9-year period stands at 3.49.


What's the latest h-index of the Investigational New Drugs?

The latest h-index of the Investigational New Drugs is 94.


Who's the publisher of the Investigational New Drugs?

The Investigational New Drugs is published by the Kluwer Academic Publishers, with its country of publication being the Netherlands.


What's the current ranking of the Investigational New Drugs?

The Investigational New Drugs is currently ranked 4625 out of 27955 Journals, Conferences, and Book Series in the latest ranking. Over the course of the last 9 years, this journal has experienced varying rankings, reaching its highest position of 2126 in 2017 and its lowest position of 4625 in 2022.


What's the abbreviation or short name for the Investigational New Drugs?

The standard ISO4 abbreviation for the Investigational New Drugs is Investig. New Drugs.


Is the "Investigational New Drugs" classified as a Journal, Conference and Proceedings, Trade Journal or Book Series?

Investigational New Drugs is classified as a journal that the Kluwer Academic Publishers publishes.


What's the scope or major areas of the Investigational New Drugs?

The Investigational New Drugs encompasses the following areas:

  • Pharmacology
  • Pharmacology (medical)
  • Oncology

For a more comprehensive understanding of its scope, check the official website of this journal.


What's the ISSN of the Investigational New Drugs?

The Investigational New Drugs is assigned the following International Standard Serial Numbers (ISSN): 01676997, 15730646.


What's the best quartile of the Investigational New Drugs?

The best quartile for the Investigational New Drugs is Q1 (2022).


What's the coverage history of the Investigational New Drugs?

The Investigational New Drugs coverage history can be summarized as follows: 1983-2022.


Credits and Sources


  • Scimago Journal & Country Rank (SJR), https://www.scimagojr.com/
  • Journal Impact Factor, https://clarivate.com/



Impact Score, h-Index, and Other Important Details of These Journals, Conferences, and Books


Journal/Conference/Workshop/Book Title Type Ranking Publisher h-index Impact Score
Historia journal 27560 Universidade Estadual Paulista 7 0.02
SPE Production and Operations Symposium, Proceedings conference and proceedings 15907 21 0.00
Archives of Phytopathology and Plant Protection journal 14852 Taylor and Francis Ltd. 29 1.14
International Journal of Applied Linguistics journal 7321 Wiley-Blackwell Publishing Ltd 51 2.00
Abacus journal 8398 Wiley-Blackwell Publishing Ltd 49 2.52
International Journal of Research and Method in Education journal 5180 Taylor and Francis Ltd. 34 2.49
Palaeontographica Abteilung B: Palaeophytologie book series 15138 E. Schweizerbart'sche Verlagsbuchhandlung 16 2.20
Libyan Studies journal 16122 Cambridge University Press 8 0.45
Proceedings of the Technical Association of the Graphic Arts, TAGA conference and proceedings 30903 Technical Association of the Graphic 8 0.00
Indian Phytopathology journal 14222 Springer Nature 11 1.33

Check complete list




Year wise Impact Score (IS) of Investigational New Drugs

Impact Score Table

Year Impact Score (IS)
2023/2024 Coming Soon
2022 3.62
2021 3.89
2020 3.29
2019 3.52
2018 2.70
2017 3.69
2016 3.71
2015 3.71
2014 3.27



Top Journals/Conferences in Pharmacology

Nature Reviews Drug Discovery
Nature Publishing Group | United Kingdom

Pharmacological Reviews
American Society for Pharmacology and Experimental Therapeutics | United States

Drug Resistance Updates
Churchill Livingstone | United States

Annual Review of Pharmacology and Toxicology
Annual Reviews Inc. | United States

Molecular Therapy
Cell Press | United States

Journal for ImmunoTherapy of Cancer
BMJ Publishing Group | United Kingdom

npj Vaccines
Nature Publishing Group | United Kingdom

Pharmacology and Therapeutics
Elsevier Inc. | United States

Trends in Pharmacological Sciences
Elsevier Ltd. | United Kingdom

Alimentary Pharmacology and Therapeutics
Wiley-Blackwell Publishing Ltd | United Kingdom

See All

Top Journals/Conferences in Pharmacology (medical)

Drug Resistance Updates
Churchill Livingstone | United States

npj Vaccines
Nature Publishing Group | United Kingdom

Pharmacology and Therapeutics
Elsevier Inc. | United States

Alimentary Pharmacology and Therapeutics
Wiley-Blackwell Publishing Ltd | United Kingdom

American Journal of Transplantation
Wiley-Blackwell Publishing Ltd | United Kingdom

Journal of Biomedical Science
BioMed Central Ltd. | United Kingdom

npj Breast Cancer
Nature Publishing Group | United Kingdom

Drugs
Adis International Ltd | United Kingdom

Rheumatology
Oxford University Press | United Kingdom

Acta Pharmacologica Sinica
Nature Publishing Group | United Kingdom

See All

Top Journals/Conferences in Oncology

Ca-A Cancer Journal for Clinicians
Wiley-Blackwell | United States

Nature Reviews Cancer
Nature Publishing Group | United Kingdom

Nature Reviews Clinical Oncology
Nature Publishing Group | United Kingdom

Cancer Cell
Cell Press | United States

Lancet Oncology, The
Elsevier Ltd. | United Kingdom

Annals of Oncology
Elsevier Ltd. | United Kingdom

Journal of Clinical Oncology
Lippincott Williams and Wilkins Ltd. | United States

Nature Cancer
| United States

Molecular Cancer
BioMed Central Ltd. | United Kingdom

JAMA Oncology
American Medical Association | United States

See All